Innate Pharma to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) announced participation in several upcoming investor conferences, focusing on oncology advancements. The conferences include:

• SVB Securities Global Biopharma Conference: February 14-16, 2023 (virtual)
• Citi's 2023 Virtual Oncology Leadership Summit: February 22, 2023 (virtual)
• H.C. Wainwright Cell Therapy Virtual Conference: February 28, 2023 (virtual)

Innate Pharma specializes in therapeutic antibodies aimed at enhancing cancer treatment. The company is recognized for its innovative approach, particularly regarding Natural Killer cell biology, and maintains significant partnerships with industry leaders.

MARSEILLE, France--(BUSINESS WIRE)-- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in the following upcoming investor conferences:

• SVB Securities Global Biopharma Conference
  Event Date: February 14 - 16, 2023 (virtual)
  
  
• Citi's 2023 Virtual Oncology Leadership Summit
  Event Date: February 22, 2023 (virtual)
  
  
• H.C. Wainwright Cell Therapy Virtual Conference
  Event Date: February 28, 2023 (virtual)

About Innate Pharma:

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate is a pioneer in the understanding of Natural Killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	Euronext: IPH Nasdaq: IPHA
LEI	9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230206005449/en/

Investors

Innate Pharma

Henry Wheeler

Tel.: +33 (0)4 84 90 32 88

Henry.wheeler@innate-pharma.fr

Media Relations

NewCap

Arthur Rouillé

Tel.: +33 (0)1 44 71 00 15

innate@newcap.eu

Source: Innate Pharma SA

FAQ

What investor conferences is Innate Pharma participating in February 2023?

Innate Pharma is participating in the following investor conferences in February 2023: SVB Securities Global Biopharma Conference (February 14-16), Citi's 2023 Virtual Oncology Leadership Summit (February 22), and H.C. Wainwright Cell Therapy Virtual Conference (February 28).

What is Innate Pharma's focus area in biotechnology?

Innate Pharma focuses on oncology, developing therapeutic antibodies that leverage the immune system to improve cancer treatment outcomes.

What is the ticker symbol for Innate Pharma?

Innate Pharma is listed on Euronext under the ticker IPH and on Nasdaq under the ticker IPHA.

Where is Innate Pharma located?

Innate Pharma is headquartered in Marseille, France, with an additional office in Rockville, MD, USA.

Who are some of Innate Pharma's partners in the biopharmaceutical industry?

Innate Pharma has partnered with major companies such as Bristol-Myers Squibb, Novo Nordisk, Sanofi, and AstraZeneca.